Concepedia
6
Publications
105
Citations
H-Index
2020
Active since
Affiliations
Amgen (United States)(Current)
UCB Pharma (United Kingdom)
UCB Pharma (Belgium)
Inserm
Université Laval
Donald Betah is an author at Amgen (United States).
Publications per year
2020–2024
Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial
Erik Fink Eriksen, Roland Chapurlat, Rogely Boyce et al. · Journal of Bone and Mineral Research · 2020 · 42 citations · Full text
3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate
E. Michael Lewiecki, Donald Betah, Ludovic Humbert et al. · Journal of Bone and Mineral Research · 2024 · 15 citations · Full text
Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension
Felicia Cosman, Mary Oates, Donald Betah et al. · Journal of Bone and Mineral Research · 2024 · 13 citations · Full text
Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment
Erik Fink Eriksen, Rogely Boyce, Yifei Shi et al. · Journal of Bone and Mineral Research · 2024 · 12 citations · Full text
Romosozumab improves microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis
Michael R. McClung, Donald Betah, Benjamin Z. Leder et al. · Journal of Bone and Mineral Research · 2024 · 12 citations · Full text
Rows per page
1–5 of 6